CVRx to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call on August 6, 2026

CVRx (NASDAQ: CVRX) announced it will release its second quarter 2026 financial and operating results after market close on Thursday, August 6, 2026.

Rhea-AI Summary

CVRx (NASDAQ: CVRX) announced it will release its second quarter 2026 financial and operating results after market close on Thursday, August 6, 2026. The company will host a conference call to review the results at 4:30 p.m. Eastern Time, with a live webcast available on its investor relations website.

Argus Jul 24 session 1 alert

-3.07% close to close 0.2x rel. volume Open Argus

Details

News Market Reaction – CVRX

$135.07M Market Cap

In the Jul 24 session, CVRX declined 3.07%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The two prior earnings-date announcements averaged a -2.25% 24-hour move, adding historical context ...

Analysis

The two prior earnings-date announcements averaged a -2.25% 24-hour move, adding historical context to this scheduling notice. The recorded active S-3 shelf, marked not effective, remains a financing-related risk to monitor.

Key Figures

Reporting period: Q2 2026 Results release date: August 6, 2026 Conference call time: 4:30 p.m. Eastern Time

Reporting period

Q2 2026

Financial and operating results

Results release date

August 6, 2026

After market close

Conference call time

4:30 p.m. Eastern Time

August 6, 2026

Previous Conferences,earnings date Reports

2 past events · Latest: Apr 27

Same Type 2 events

1. Apr 27

   Q1 earnings date

   24h Move

   -2.2%

   Announced May 11 release date and conference call for first-quarter results

2. Jan 29

   Q4 earnings date

   24h Move

   -2.3%

   Announced February 12 release date and conference call for fourth-quarter results

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

neuromodulation

1 terms

neuromodulation medical

"focused on developing, manufacturing and commercializing innovative neuromodulation solutions"

Neuromodulation is the use of devices or targeted treatments to change how nerves or brain circuits send signals, much like adjusting the volume or tuning on an audio system to alter what you hear. For investors, it matters because these therapies can treat chronic conditions (pain, movement disorders, depression) where existing medicines fall short, creating potential markets, regulatory milestones, and durable revenue streams if technologies prove safe and effective.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MINNEAPOLIS, July 23, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release second quarter 2026 financial and operating results after market close on Thursday, August 6, 2026. The Company will host a conference call to review its results at 4:30 p.m. Eastern Time the same day.

A live webcast of the investor conference call will be available online at the investor relations page of the Company’s website at ir.cvrx.com. To listen to the conference call on your telephone, please dial 1- 877-704-4453 for U.S. callers, or 1-201-389-0920 for international callers, approximately ten minutes prior to the start time.

About CVRx, Inc.

CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Investor Contact:
Mark Klausner or Mike Vallie
ICR Healthcare
443-213-0501
ir@cvrx.com

Media Contact:
Emily Meyers 
CVRx, Inc. 
763-416-2853
emeyers@cvrx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will CVRx (NASDAQ: CVRX) report its Q2 2026 earnings results?

CVRx plans to report its Q2 2026 financial and operating results after market close on Thursday, August 6, 2026. According to CVRx, the release will be followed by a same-day investor conference call.

What time is the CVRx Q2 2026 earnings conference call on August 6, 2026?

The CVRx Q2 2026 earnings conference call is scheduled for 4:30 p.m. Eastern Time on August 6, 2026. According to CVRx, investors should dial in about ten minutes before the start time.

How can investors access the CVRx (CVRX) Q2 2026 earnings webcast?

Investors can access the CVRx Q2 2026 earnings webcast via a live stream on the investor relations page at ir.cvrx.com. According to CVRx, the webcast will run concurrently with the conference call.

What are the dial-in numbers for the CVRx Q2 2026 earnings call?

For the CVRx Q2 2026 call, U.S. investors should dial 1-877-704-4453, and international callers should dial 1-201-389-0920. According to CVRx, participants should call about ten minutes before the scheduled start.

Do I need to register in advance for the CVRx (CVRX) Q2 2026 earnings conference call?

The announcement does not mention advance registration; investors are instructed to dial in approximately ten minutes early. According to CVRx, access is available by phone or webcast via its investor relations website.